2004
- FDA approves Sensipar (cinacalcet HCl) for the treatment of secondary hyper-parathyroidism in chronic kidney disease patients on dialysis and for the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma
- FDA approves Enbrel for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- FDA approves Enbrel for the treatment of ankylosing spondylitis and other expanded indications
- FDA approves Enbrel to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis
- FDA approves Neulasta to decrease the incidence of infection in patients with non-myeloid cancers receiving myelosuppressive chemotherapy
- Amgen completes Immunex acquisition
- FDA approves Aranesp for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies
- FDA approves Amgen's Rhode Island manufacturing facility for Enbrel
- FDA approves Kineret to treat the signs and symptoms in patients with moderately to severely active rheumatoid arthritis whose disease has failed to respond to one or more disease-modifying medicines
- Kevin W. Sharer named chairman
- FDA approves Aranesp to treat anemia associated with chronic renal failure, including patients on dialysis and not on dialysis
- Kevin Sharer named CEO
- Amgen acquires Kinetix Pharmaceuticals
- Gordon M. Binder retires
- Amgen reaches sales of more than $3 billion
- FDA approves Enbrel to treat patients with moderately to severely active polyarticular-course juvenile rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines
- FDA approves Neupogen for use in support of treatment of acute myeloid leukemia
- FDA approves Enbrel to treat patients with rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines
- FDA approves Infergen for treating patients with Hepatitis C
- FDA approves Epogen for reduction of allogeneic blood transfusion in surgery patients
- Amgen reaches sales of more than $2 billion
- FDA approves Neupogen for use in peripheral blood progenitor cell transplants
- FDA approves Neupogen for patients undergoing bone marrow transplantation and for patients with severe chronic neutropenia
- Amgen receives U.S. Dept. of Commerce National Medal of Technology
- Amgen completes acquisition of Synergen
- FDA approves Epogen for treatment of anemia in cancer patients on chemotherapy
- Kevin W. Sharer elected President and COO
- Amgen reaches sales of more than $1 billion
- Amgen added to the S&P 500
- FDA approves Neupogen to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers receiving myelosuppressive therapy
- Amgen establishes the Amgen Foundation for charitable giving
- Neupogen named "Product of the Year" by Fortune magazine
- George B. Rathmann retires
- Gordon M. Binder elected Chairman of Amgen's Board of Directors
- Immunex clones TNF receptor, later patented and named Enbrel
- Amgen receives first U.S. patent for recombinant G-CSF Neupogen
- FDA approves Epogen for the treatment of anemia in patients with end-stage renal disease
- Epogen named "Product of the Year" by Fortune magazine
- Amgen added to the NASDAQ 100 Index
- Gordon M. Binder elected CEO
- Company changes name to Amgen Inc. and becomes a Delaware corporation
- Amgen receives first patent on DNA used in producing Epogen
- George B. Rathmann elected chairman of Amgen's board of directors
- Larry M. Souza's team clones granulocyte colony-stimulating factor (G-CSF), later patented and named Neupogen
- Company changes name to Amgen
- A team led by Fu-Kuen Lin clones erythropoietin, later patented and named Epogen
- IPO of 2,350,000 shares at $18 per share results in $40 million raised; ticker symbol: AMGN
- Company changes name to Applied Molecular Genetics Inc.
- Venture capitalists Bill Bowes, Franklin "Pitch" Johnson, Sam Wohlsteadter and Raymond Baddour establish AMGen (Applied Molecular Genetics Inc.) as a California corporation on April 8
- George B. Rathmann elected president and CEO
